Ifp Advisors, Inc Voyager Therapeutics, Inc. Transaction History

Ifp Advisors, Inc

$3.07 Billion
Q1 2025

A detailed history of Ifp Advisors, Inc transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Ifp Advisors, Inc holds 25 shares of VYGR stock, worth $73. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 25 -0.0%

Holding current value

$73

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 04, 2025	BUY	$5.27 - $8.07 $131 - $201	25 New	25 $0
Q3 2021 Oct 06, 2021	SELL	$2.63 - $4.12 $0 - $0	0 Closed	0 $0
Q2 2021 Jul 13, 2021	BUY	$3.94 - $5.44 $0 - $0	0 New	0 $0
Q1 2021 Apr 30, 2021	BUY	$4.61 - $9.04 $0 - $0	0 New	0 $0
Q4 2020 Jan 25, 2021	BUY	$7.15 - $12.28 $0 - $0	0 New	0 $0
Q3 2020 Oct 29, 2020	BUY	$10.01 - $13.75 $0 - $0	0 New	0 $0
Q2 2020 Aug 05, 2020	SELL	$8.05 - $14.21 $1,207 - $2,131	-150 Closed	0 $0
Q3 2019 Nov 07, 2019	SELL	$16.31 - $28.29 $4,077 - $7,072	-250 Reduced 62.5%	150 $3,000
Q1 2019 May 15, 2019	SELL	$8.0 - $19.66 $2,000 - $4,915	-250 Reduced 38.46%	400 $8,000
Q2 2018 Aug 07, 2018	SELL	$16.76 - $23.92 $1,676 - $2,392	-100 Reduced 13.33%	650 $0
Q1 2018 Jun 03, 2019	BUY	$16.16 - $31.31 $1,616 - $3,131	100 Added 15.38%	750 $12,000
Q1 2018 May 09, 2018	SELL	$16.16 - $31.31 $1,616 - $3,131	-100 Reduced 13.33%	650 $0
Q4 2017 Jan 24, 2018	BUY	$12.26 - $25.88 $1,226 - $2,588	100 Added 15.38%	750 $0
Q3 2017 Oct 30, 2017	BUY	$8.37 - $20.59 $2,092 - $5,147	250 Added 62.5%	650 $13,000
Q1 2016 Jun 03, 2019	BUY	N/A	400	400 $8,000

Others Institutions Holding VYGR

# of Institutions

121

Shares Held

34.6M

Call Options Held

12.9K

Put Options Held

37.7K

View Full List

About Voyager Therapeutics, Inc.

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $113M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

More about VYGR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ifp Advisors, Inc with notifications on news.

Account